KOPRANNSEKopran Limited· PharmaceuticalsMediumNeutral
Announced Mon, 18 May · 19:50 IST

Kopran Limited has informed the Exchange about issue of Securities in its subsidiary company

Ownership Changes View source PDF

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹164.00
prior close
₹165.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4+0.3+1.1+1.0+2.4+1.4+0.0+15.2+17.8+25.3+10.7+18.3+23.8
Up moveDown movePending
AI summary

Kopran Limited's subsidiary, Kopran Research Laboratories Limited (KRLL), has announced a rights issue of shares. The issue offers 1 share for every 12 shares held, with a face value of Rs. 10 and a premium of Rs. 90 per share. The subsidiary plans to raise Rs. 18.75 crore for working capital requirements. Additionally, Mr. Chandresh Gandhi has been appointed as an Additional Director (Independent, Non-Executive) on the KRLL board for a 5-year term from May 18, 2026 to May 17, 2031, subject to shareholder approval. Mr. Gandhi is a Chartered Accountant with over 30 years of professional experience.

Likely market impact

The rights issue by the subsidiary will raise working capital but may dilute Kopran Limited's stake in KRLL if the parent company does not fully participate in the rights issue. Shareholders should monitor whether Kopran Limited participates to maintain its holding percentage.